A Questionnaire Survey about the Practical Techniques of the Therapy with Botulinum Toxin
|
Accession number;06A0654493
|
| Title;A Questionnaire Survey about the Practical Techniques of the Therapy with Botulinum Toxin |
| Author;
MEZAKI TAKAHIRO
(Orinkai, Sakakibara Hakuho Byoin)
HAYASHI AKITO
(Juntendo Univ., JPN)
NAKASE HIROFUMI
(Toranomonbyoin)
HASEGAWA KAZUKO
(Sagamiharabyouin)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.425-431(2006)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.7 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A questionnaire was sent out to 28 expert doctors asking about how they are practicing therapy with botulinum toxin for blepharospasm (BSM) and cervical dystonia (CD), to demonstrate its state of the art in Japan and to prepare for a standardized treatment guideline for dystonia with botulinum toxin type A. The questionnaire consisted of inquiries about the routine procedures of the treatment We received 15 replies (54%), which indicated diverse methodologies of the treatment among doctors; the content of pre-treatment information given to patients (cost, adverse reactions, or other details of the toxin injection); concentration of the toxin solution (1-8ml/100 units for BSM and 1-4ml/100 units for CD); needle thickness (23-30 gauges for BSM and 21-27 gauges for CD) and length (12-25mm for BSM and 10-60mm for CD) used for injection; posture by injection (recumbent for BSM or sitting for BSM [1 reply] and CD); the maximum depth of needle insertion for posterior cervical muscles (13-35mm [50mm under EMG monitoring]) ; post-treatment instructions about rest, face wash, bathing, exercise, drinking, how to treat lid weakness after injection for BSM, and about other points to note; EMG guidance (unnecessary or necessary [1 reply] for BSM, and unnecessary, necesaary only in specified cases, or necessary for CD); potential target muscles in exemplified cases with BSM or apraxia of lid opening (the orbicularis oculi and other periocular muscles if necessary) and CD (shown in Table); times required for the treatment (shown in Figures). Based on these results, the consensus guideline has to be prepared for the treatment of BSM and CD with botulinum toxin type A to further improve its efficacy. (author abst.) |
|
|
|
Related Articles;
|
|
